World Tumor Markers Testing Market 2014: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers

Complete report $32,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.

Highlights

- Identifies and evaluates major business opportunities emerging in the tumor marker market during the next five years

- Examines trends in the U.S., Europe and Japan

- Reviews current and emerging tumor markers

- Analyzes applications of emerging diagnostic technologies

- Forecasts sales of major tumor markers by country and market segment

- Profiles leading market players and potential entrants

- Suggests alternative business expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.  During the next ten years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field.  Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.  The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Geographic Coverage

- France

- Germany

- Italy

- Japan

- Spain

- UK

- USA

Market Segmentation Analysis

- Sales and market shares of major suppliers, by individual tumor marker

and country.

- Five-year test volume and sales forecasts for major

tumor markers by country and market segment,

including:

- Hospitals

- Commercial/Private Laboratories

- Physician Offices/Group Practices

- Cancer Clinics

- Ambulatory Care Centers

- Comprehensive market segmentation analysis, including review

of the market dynamics, structure, size, growth and major suppliers

by country.

- Cancer statistics, etiology and recent developments in the

U.S., Japan and five major European countries.

Current and Emerging Products

- Review of over 200 current and emerging tumor markers,

including:

- Biochemical Markers

- Oncogenes

- Growth Factors

- Hormones

- Colony Stimulating Factors

- Lymphokines

- Immunohistochemical Stains, and others.

- Analysis of major immunoassay analyzers used for

tumor marker testing, including their operating characteristics,

features and selling prices.

Technology Review

- Assessment of monoclonal antibodies, immunoassays, DNA

probes, biochips/microarrays, chromosome analysis, IT,

artificial intelligence, flow cytometry, biosensors, and their

potential applications for tumor marker testing.

- Review of competing/complementing technologies, including

CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of over 500 companies, universities and

research centers developing new tumor markers and detection technologies.

Competitive Assessments

- Extensive strategic assessments of  major suppliers

and start-up firms developing innovative

technologies and products, including their sales,

product portfolios, marketing tactics, collaborative

arrangements and new products in R&D.

Worldwide Market Overview

- Estimated universe of laboratories performing tumor marker testing

by country.

- Five-year test volume and sales projections by country.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially

significant market appeal during the next ten years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Methodology

This report is based on interviews with clinical pathologists, laboratory directors,

executives from leading diagnostic companies and start-up firms

developing innovative products, university scientists, as well as

experts from industry associations, venture capital firms and the

investment banking community in the U.S., five major European

countries and Japan.

The market projections are also based on questionnaire

responses received from hospitals, commercial/private laboratories,

physician offices/group practices, cancer clinics and ambulatory

care centers in seven countries.

In addition to primary sources of information, a comprehensive

review of the most recent technical and business publications, manufacturer

product literature, patents, trade association surveys, government

studies, marketing and technical meeting presentations,

industry analyst reports, and VPG's proprietary data files was conducted.

Contains 1,200 pages and 450 tables